Drugs / BI 3032950
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05985200 | Sep 2023 → Aug 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05518708 | Sep 2022 → Sep 2023 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06636656 | Dec 2024 → Jul 2027 expected | ulcerative colitis | Boehringer Ingelheim | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 3032950 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06636656 ↗ |
| Route | Intravenous | “Administered as intravenous infusion” NCT05518708 ↗ |